Transforming drug development with a fully outsourced model: Lessons learned for biopharmaceuticals

摘要

The pharmaceutical industry is exploring alternative drug development models to address the persistent decline in productivity. One transformation model that has been implemented successfully in early phase development is Eli Lilly and Company's Chorus). Chorus is an example of research and development (R&D) transformation rather than a corporate downsizing exercise. Lessons learned from Lilly's Chorus outsource model may be applied to biotechnology and pharmaceutical companies, as well as Contract Research Organizations. Application of Chorus principles could result in similar productivity gains in both the early and late phases of drug development.